Quest Diagnostics Incorporated (DGX)
DGX moved a median of +0.03% 30 minutes after news, and +0.15% by the close. How DGX actually reacts to news — the realized, point-in-time move the market made, measured across 524 labeled events over the last three years with zero look-ahead.
DGX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 50% | 522 |
| 30-min | +0.03% | 51% | 523 |
| 60-min | +0.15% | 57% | 523 |
| to close | +0.15% | 55% | 521 |
| Middle 50% of DGX reactions | -0.30% to +0.73% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 524 |
Half of all Quest Diagnostics Incorporated news events land between -0.30% and +0.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DGX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 44 | +0.10% | 61% | +0.07% |
| Analyst downgrades | 31 | -0.08% | 36% | +0.21% |
| Coverage initiations | 11 | -0.47% | 46% | -0.34% |
| Rating reiterations | 91 | +0.03% | 53% | -0.09% |
| Price-target raises | 51 | -0.04% | 41% | -0.11% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how DGX ranks against every other measured name →
That’s how DGX usually reacts — get an email when it moves on news →Email me when DGX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DGX's baseline. Nothing else.
Recent DGX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K QUEST DIAGNOSTICS INC For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.05% | -0.64% | |
| Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials | Press release | PR Newswire | -0.14% | -0.71% | |
| Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 | Press release | PR Newswire | +0.57% | -0.95% | |
| Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics | Press release | PR Newswire | +0.03% | -0.91% | |
| Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics | Press release | PR Newswire | +0.57% | +0.66% | |
| Apple Health app Users to be Able to Order Labs from Quest Diagnostics | Press release | PR Newswire | -0.55% | -2.19% | |
| Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com | Press release | PR Newswire | -0.23% | +0.24% | |
| Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference | Press release | PR Newswire | -0.25% | +0.23% | |
| Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology | Press release | PR Newswire | +0.31% | -0.04% | |
| Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | PR Newswire | +0.31% | -0.04% | |
| WHOOP Makes Advanced Labs Available Without a Wearable Membership | Press release | Business Wire | +0.01% | -0.74% | |
| Quest Diagnostics Declares Quarterly Cash Dividend | Press release | PR Newswire | +0.17% | -1.28% | |
| Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics | Press release | PR Newswire | -0.35% | +1.47% | |
| Form 10-Q QUEST DIAGNOSTICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.01% | -0.06% | |
| Form 8-K QUEST DIAGNOSTICS INC For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +4.08% | +1.29% | |
| Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 | Press release | PR Newswire | +4.08% | +1.29% | |
| One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns | Press release | PR Newswire | -0.32% | -0.39% | |
| Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI | Press release | PR Newswire | -0.82% | -1.20% | |
| Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing | Press release | PR Newswire | +0.79% | +2.37% | |
| Form 11-K QUEST DIAGNOSTICS INC For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | +0.31% | -0.28% | |
| UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics | Press release | PR Newswire | +0.14% | -0.86% | |
| Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026 | Press release | PR Newswire | +0.26% | -0.88% | |
| Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report | Press release | PR Newswire | +0.29% | -0.98% | |
| Form 8-K QUEST DIAGNOSTICS INC For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | +0.63% | |
| Quest Diagnostics Declares Quarterly Cash Dividend | Press release | PR Newswire | -0.37% | +0.98% | |
| Form 8-K QUEST DIAGNOSTICS INC For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | +1.31% | |
| Form 8-K QUEST DIAGNOSTICS INC For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | +0.39% | |
| Quest Diagnostics Prices $500 Million of Senior Notes | Press release | PR Newswire | -0.39% | -1.78% | |
| Form 10-Q QUEST DIAGNOSTICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.14% | -2.80% | |
| Form 8-K QUEST DIAGNOSTICS INC For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.22% | |
| Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 | Press release | PR Newswire | +0.00% | -0.22% | |
| City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers | Press release | PR Newswire | +0.93% | +0.13% | |
| Form DEF 14A QUEST DIAGNOSTICS INC For: May 20 | SEC filing · Form DEF | SEC EDGAR | +0.25% | -1.34% | |
| Form DEFA14A QUEST DIAGNOSTICS INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.25% | -1.34% | |
| MyGevity Launches Platform That Connects Your DNA to Real-Time Lab Results -- Redefining At-Home Longevity Testing | Press release | PR Web | -0.65% | -1.49% | |
| Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026 | Press release | PR Newswire | +0.18% | -1.02% | |
| Form 8-K QUEST DIAGNOSTICS INC For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | — | |
| Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors | Press release | PR Newswire | -0.04% | — | |
| Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results | Press release | PR Newswire | -0.28% | -1.07% | |
| Form 10-K QUEST DIAGNOSTICS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.09% | +0.39% | |
| Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer | Press release | PR Newswire | -0.04% | +1.17% | |
| Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference | Press release | PR Newswire | +0.00% | -0.32% | |
| Form 8-K QUEST DIAGNOSTICS INC For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | +4.24% | |
| Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization | Press release | PR Newswire | +1.35% | +4.24% | |
| Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share | Press release | PR Newswire | +1.35% | +4.24% | |
| Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease | Press release | PR Newswire | -0.65% | -0.54% | |
| Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year | Press release | PR Newswire | +0.10% | -1.20% | |
| Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect | Press release | PR Newswire | -0.01% | +1.66% | |
| Form 8-K QUEST DIAGNOSTICS INC For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +1.75% | |
| Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 | Press release | PR Newswire | -0.18% | -1.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DGX section they belong to.
Where else DGX is measured.
DGX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd (RDY) | 528 | 0.00% | 47% |
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 524 | -0.32% | 46% |
| STAAR Surgical Company (STAA) | 522 | -0.21% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Quest Diagnostics Incorporated's median reaction calculated?
Every labeled DGX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 524 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of DGX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DGX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.